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Abstract
Cancer stem cells (CSC) are predicted to be critical drivers of
tumor progression due to their self-renewal capacity and
limitless proliferative potential. An emerging area of research
suggests that CSC may also support tumor progression by
promoting tumor angiogenesis. To investigate how CSC
contribute to tumor vascular development, we used an
approach comparing tumor xenografts of the C6 glioma cell
line containing either a low or a high fraction of CSC.
Compared with CSC-low tumors, CSC-high tumors exhibited
increased microvessel density and blood perfusion and
induced increased mobilization and tumor recruitment of
bone marrow–derived endothelial progenitor cells (EPC).
CSC-high C6 cell cultures also induced higher levels of
endothelial cell proliferation and tubule organization in vitro
compared with CSC-low cultures. CSC-high cultures and
tumors expressed increased levels of the proangiogenic
factors vascular endothelial growth factor and stromal-
derived factor 1, and when signaling by either factor was
blocked, all aspects of angiogenesis observed in CSC-high
cultures and tumors, including microvessel density, perfusion,
EPC mobilization/recruitment, and stimulation of endothelial
cell activity, were reduced to levels comparable with those
observed in CSC-low cultures/tumors. These results suggest
that CSC contribute to tumor angiogenesis by promoting both
local endothelial cell activity and systemic angiogenic pro-
cesses involving bone marrow–derived EPC in a vascular
endothelial growth factor–dependent and stromal-derived
factor 1–dependent manner. [Cancer Res 2009;69(18):7243–51]
Introduction
Significant progress has been made in identifying stem cell-like
fractions of tumor cells in a wide variety of human cancers, and
characterizing their key properties, which include high tumor-
initiating potential, self-renewal, and multilineage differentiation
capabilities, and the expression of ‘‘stemness’’ pathways involved in
the maintenance of these properties (1). The features of the cancer
stem cell (CSC) fraction suggest that they may be critical in
sustaining tumor progression, and it is therefore increasingly
important to further our understanding of this unique cell
population and how it affects tumor biology. In this regard, an
emerging area of research suggests that CSC, in addition to their
proliferative capabilities, may have a role in promoting tumor
angiogenesis.
A study by Bao and colleagues (2) found that the CSC-enriched
CD133+ fraction of human glioma cells had a significantly stronger
capacity to promote angiogenesis than the CSC-depleted CD133
fraction. CD133+ cells consistently yielded aggressive, highly
vascularized tumors when implanted in mice, whereas CD133
cells were rarely tumorigenic and gave rise to tiny, poorly
vascularized tumors. The proangiogenic capacity of the CD133+
fraction was attributable to vascular endothelial growth factor
(VEGF) activity. Other studies are consistent with the results of Bao
and colleagues and further suggest a proangiogenic role for CSC.
For example, CD133+ CSC from the U87 human glioblastoma cell
line expressed more VEGF and gave rise to more angiogenic
xenograft tumors compared with their CD133, non-stem-like
counterparts (3). CSC-enriched spheroid cultures of the MCF7
human breast cancer cell line have also been reported to express
more VEGF than matched monolayer cultures with a lower CSC
fraction (4). Similarly, CSC-enriched neurospheres derived from the
GL261 murine glioma cell line express more VEGF and display a
more proangiogenic expression signature based on microarray
analysis compared with adherent, CSC-low GL261 cultures (5).
Tumor vascular development is a multifactorial process,
incorporating both sprouting angiogenesis, in which tumor-derived
factors promote nascent capillary formation by endothelial cells in
the local tumor microenvironment, and adult vasculogenesis, in
which bone marrow–derived endothelial progenitor cells (EPC)
home to the tumor site, differentiate into mature endothelial cells,
and incorporate into growing tumor vessels (6–13). Additionally,
several other bone marrow–derived cell (BMDC) types can be
recruited to sites of active angiogenesis, where they may promote
angiogenesis in a paracrine manner (6, 14–19). To gain a more
thorough understanding of how CSC contribute to blood vessel
growth in tumors, we investigated how the stem-like cell fraction
from the rat C6 glioma cell line influences tumor angiogenesis,
endothelial cell organization and proliferation, and mobilization
and recruitment of BMDC.
Materials and Methods
Cell culture. C6 (American Type Culture Collection) were maintained as
monolayers [CSC-low, serum-containing (Ser+) condition] or nonadherent
tumor spheres [CSC-high, serum-free supplemented (SFS) condition] as
described (20). Human umbilical vein endothelial cells (HUVEC; Cambrex
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Bioscience Walkersville) were maintained as described (21). Adherent cells
were harvested with 0.25% trypsin-0.03% EDTA (Invitrogen), and tumor
spheres were dissociated by mechanical trituration.
Mice and tumor xenografts. For most experiments, 6- to 8-week-old
female athymic nude mice (Harlan) were injected s.c. with 2  106 C6 cells
in 200 AL serum-free DMEM.
Tumor sphere-forming assay. Tumor sphere-forming assay was done
as described (21).
Limiting dilution tumor initiation assay. Nude mice were injected
with 100, 1000, 5000, 10,000, or 50,000 C6 cells. Mice were monitored for
3 months and scored as positive (palpable tumor) or negative.
Immunofluorescent staining of cytospins and tumor sections. For
cytospins, 100,000 cells in DMEM + 10% fetal bovine serum were loaded in
Shandon cytofunnels (Fisher Scientific) and cytocentrifuged onto glass
microscope slides. Tumors were frozen over dry ice in Tissue-Tek OCT
(Miles) and sectioned (5-8 Am). Cells/tissues were fixed in 4% paraformal-
dehyde and blocked with 10% goat serum. Antibodies were diluted in DAKO
antibody diluent, and incubations were done at room temperature. Where
indicated, cells/tissues were counterstained with 1 Ag/mL 4¶,6-diamidino-2-
phenylindole (Molecular Probes). Images were acquired using a Zeiss
Axioplan 2 with Zeiss Axiocam and Axio Vision 4.6.3 software and analyzed
using Adobe Photoshop 6.0.
Antibodies. Antibodies used include purified mouse anti-rat nestin
(1:100; BD Biosciences) with Texas red–conjugated goat anti-mouse
secondary (1:200; Jackson ImmunoResearch Laboratories), rat anti-mouse
CD31 (1:100; BD Biosciences) with Cy3-donkey anti-rat secondary (1:200;
Jackson ImmunoResearch Laboratories), and rabbit polyclonal anti-VEGF
(1:50) or anti–stromal-derived factor 1 (SDF1; 1:50; Santa Cruz Biotechnol-
ogy) with Cy3-goat anti-rabbit secondary (1:100; Jackson ImmunoResearch
Laboratories).
Perfusion assay. Mice were injected i.v. with 40 mg/kg Hoechst 33342
(Sigma) in PBS. After 1 min, mice were euthanized and tumors were excised,
sectioned, and imaged as above.
Generation of C6 conditionedmedium. C6 cells were plated in DMEM+
2% fetal bovine serum at 1.25  106/mL and incubated at 37jC. After
24 h, culture medium was harvested and spun down, and supernatants
were stored at 80jC.
Endothelial cell proliferation assays. HUVEC were plated at 3,000 per
well in 200 AL HUVEC medium in 1% gelatin-coated 96-well microplates
and allowed to attach overnight. C6 conditioned medium was supple-
mented with 10 units/mL heparin, and aliquots were supplemented with
1,000 Amol/L AMD3100, a small-molecule antagonist of the SDF1 receptor
CXCR4 (ref. 22; Sigma), or 100 Ag/mL IMC1121-b, a monoclonal anti-human
VEGF receptor (VEGFR) 2 antibody (ref. 23; ImClone Systems). HUVEC were
incubated with 100 AL/well conditioned medium F drug at 37jC for 18 h,
after which cells were pulsed with 2 ACi [3H]thymidine for 6 h.
Endothelial cell tubule formation assays. C6 conditioned medium was
supplemented with 10 units/mL heparin and 10% fetal bovine serum, and
aliquots were supplemented with 200 Amol/L AMD3100 or 100 Ag/mL
IMC1121-b. HUVEC were suspended in conditioned medium F drug at
100,000/mL, and 300 AL/well were plated on Matrigel-coated Lab-Tek II
8-well chamber slides (Nunc) and incubated at 37jC for 20 h. Images were
acquired using a Zeiss Axioplan 2 (bright-field, 100) with attached Zeiss
Axiocam and Axio Vision 4.6.3 software, and tubule length was measured
using ImageJ image analysis software (NIH).
ELISA and Western blotting. Conditioned medium was analyzed
undiluted using Quantikine mouse VEGF ELISA kit (R&D Systems)
according to the manufacturer’s instructions. For Western blotting, whole-
cell lysates were prepared as described (24). Proteins from conditioned
medium samples were precipitated by mixing 1 mL:5 mL with methanol
and incubating for 1 h at 80jC, pelleted, and dried. Western blotting done
as described (24).
Bone marrow reconstitution. Bone marrow cells harvested from
femurs of athymic nude-green fluorescent protein (GFP) mice (ref. 25;
Fig. 4C and D ; AntiCancer) or UBI-GFP/BL6 mice (Figs. 4B and C and 6C ;
The Jackson Laboratory) were injected into the tail veins of lethally
Figure 1. Relative CSC content in C6 Ser+ and SFS cultures and tumors. A, tumor sphere-forming assay: 100 cells plated per well. B, cytospins of C6 cultures stained
for nestin (Texas red; red). Nuclei stained with 4¶,6-diamidino-2-phenylindole (blue ), 200. Histogram: image analysis of nestin staining. Eight fields analyzed per
group. Cells displaying Texas red fluorescence above background (established using Texas red–conjugated IgG control) were counted as nestin-positive.
% Nestin-positive cells per field calculated as nestin-positive cells/DAPI–stained cells (counted manually). C, ex-vivo tumor sphere-forming assay using established
tumors (4 wk post-implantation).
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irradiated (900 rads), 6- to 8-week-old female athymic nude mice (Harlan;
107 cells per mouse). Mice were used in subsequent experiments after
8 weeks to allow for reconstitution.
Visualization of tumor vessel–associated BMDC. Sections of tumors
grown in GFP bone marrow–reconstituted mice were stained for CD31 as
above and visualized using a Zeiss Axiovert 100 with LSM510 confocal
imaging system and Zeiss Advanced Imaging Microscopy software.
Flow cytometry. Circulating EPC were evaluated using flow cytometry
as described (26). For analysis of tumor-recruited BMDC, single-cell
suspensions were prepared as above. Cells were stained according to the
antibody manufacturer’s instructions. Tumor-recruited bone marrow–
derived endothelial cells were defined as GFP+/VEGFR2+/CD31+/CD45,
recruited bone marrow–derived circulating cells (RBCC)/hemangiocytes as
CXCR4+/CD11b+/VEGFR1+/CD45+, and Tie2-expressing monocytes (TEM)
as Tie2+/CD11b+/VEGFR1+/CD45+. At least 50,000 events per sample were
acquired, and at least 100 events were acquired in the final gate of each
experiment. All antibodies were purchased from BD Biosciences.
VEGF and SDF1 blocking experiments in vivo. Mice with palpable C6
tumors (7-12 days post-implantation) were treated for 2 weeks with the
anti-mouse VEGFR2 blocking monoclonal antibody DC101 (ref. 27; ImClone
Systems; in PBS, 800 Ag/mouse/3 days i.p.) or AMD3100 (in PBS, 5 mg/kg/d
s.c.). Control animals received PBS.
Statistical analysis. Histograms represent mean F SE. Asterisks in
figures denote analysis versus matched CSC-low groups (Student’s t test):
***, P < 0.001; **, P < 0.01; *, P < 0.05.
Results
C6 tumor sphere cultures are enriched in CSC and give rise
to CSC-enriched xenograft tumors. Previous studies on the
proangiogenic nature of CSC, such as the one by Bao and
colleagues (2), have compared fluorescence-activated cell sorting–
sorted CSC and non-CSC populations. One difficulty with this
approach is that, as Bao and colleagues reported, the non-CSC
population rarely gives rise to tumors, and when it does, they are
extremely growth-limited and poorly vascularized. Although in this
situation it is tempting to conclude that the non-CSC-derived
tumors are poorly vascularized due to lack of angiogenic capacity
in the non-CSC fraction, it is also possible that, due to its inherent
lack of proliferative potential, the non-CSC fraction failed to drive
tumor growth to a point where the angiogenic switch was initiated.
To avoid such difficulties in the interpretation of our results, we
used an approach comparing the angiogenic properties of size-
matched, progressively growing tumors with either low or high
CSC content to study how the CSC fraction influences tumor
vascular development.
The C6 rat glioma cell line contains a CSC fraction that can be
expanded by prolonged culture in serum-free medium (20). We
took advantage of this property and generated long-term C6
cultures grown either as monolayers in serum-containing media
(Ser+ condition) or as nonadherent tumor spheres in serum-free
medium (SFS condition) supplemented as described (20). Consis-
tent with the results of Kondo and colleagues (20), our C6 SFS
cultures were significantly enriched in CSC compared with the C6
Ser+ cultures as evidenced by increased formation of tumor
spheres at clonal density in serum-free conditions (Fig. 1A),
increased expression of the neural precursor marker nestin
(Fig. 1B), and increased tumor-initiating capacity when implanted
Table 1. Limiting dilution tumor initiation assay
No. C6 cells injected Tumor take
(sites engrafted/injected)






NOTE: Five mice per dilution, right and left flanks were injected, for a
total of 10 injections per dilution. Results at 5,000 cell dilution are
significantly different (P = 0.0198, Fisher’s exact test).
Figure 2. Microvessel density and blood perfusion in CSC-low and CSC-high tumors. A, top, CD31+ microvessels (Cy3; red ), 200; bottom, blood perfusion (Hoechst;
blue ), 100. B, image quantification of microvessel density: number of CD31+ (red ) structures per field (counted manually). C, image quantification of blood
perfusion: total Hoechst fluorescence intensity (total colored pixels  mean fluorescence intensity) per field. Five mice per group, five fields analyzed per tumor.
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s.c. in nude mice at limiting dilution (Table 1). The difference in
tumor-initiating capacity was only noticeable when 5,000 cells were
injected. A possible explanation for this is that, at the next highest
dilution (10,000 cells), there is a sufficient number of tumorigenic
cells in both groups to initiate a tumor and, at the next lowest
dilution (1,000 cells), there is an insufficient number of tumorigenic
cells in either group. Another possible contributing factor is that, at
the lowest dilutions in our assay, the likelihood that sufficient
numbers of tumorigenic cells remain healthy throughout the
xenotransplant process and retain their ability for tumor ‘‘take’’ is
reduced. Ser+- and SFS-derived tumors grew at similar rates when
5,000 or 10,000 cells were injected, although, when 50,000 cells were
injected, the growth rate of Ser+-derived tumors was somewhat
faster, and this difference was statistically significant (Supplemen-
tary Fig. S1). This difference in growth rate may be reflective of the
slower cycling time associated with stem-like cells.
After 4 weeks of tumor growth, cells from dissociated SFS-
derived tumors still formed significantly more tumor spheres at
clonal density than cells from Ser+-derived tumors (Fig. 1C),
indicating that CSC-low (Ser+) and CSC-high (SFS) cultures give
rise, respectively, to tumors that maintain a sustained low or high
fraction of self-renewing CSC.
Tumor volume matching. To account for the noted difference
in growth rate, in each subsequent in vivo experiment where CSC-
low and CSC-high tumors are compared, tumors were selected
such that the average tumor volume between groups was not
significantly different.
Increased vessel density and blood perfusion in CSC-high
tumors. To determine the effect of the CSC fraction on tumor
angiogenesis, Ser+ or SFS cells were implanted s.c. in nude mice.
After 3 weeks, tumor microvessel density and blood perfusion were
assessed. Both microvessel density (Fig. 2A, top, b) and perfusion
(Fig. 2A, bottom, c) were significantly higher in CSC-high tumors,
suggesting that the CSC fraction has a role in promoting tumor
vascular development.
Increased promotion of endothelial cell proliferation and
tubule formation by CSC-high cultures. To gain insight into the
mechanisms underlying the increased angiogenesis observed in
CSC-high tumors, we investigated the effects of secreted factors
from CSC-low and CSC-high C6 cultures on vascular endothelial
cells in vitro . HUVEC were plated with either CSC-low or CSC-high
conditioned medium, and proliferation was measured by radio-
labeled thymidine incorporation assay. Similarly, HUVEC were
plated on Matrigel with C6 conditioned medium to assess
formation of capillary-like tubule networks. Higher degrees of both
endothelial cell proliferation (Fig. 3A and B) and tubule formation
(Fig. 3C) were promoted by CSC-high conditioned medium,
suggesting that CSC may promote angiogenesis in part by
stimulation of endothelial cell activity.
Increased endothelial progenitor mobilization and BMDC
recruitment in mice with CSC-high xenograft tumors. Another
contributing factor to tumor vascular development is the
recruitment of various proangiogenic BMDC populations. These
include EPC, which enter the circulation in response to tumor-
derived proangiogenic factors and home to the tumor where they
can incorporate into nascent capillaries (6–13). Other BMDC,
including RBCC/hemangiocytes (14, 15), TEM (16, 17), tumor-
associated dendritic cells (18), and tumor-associated stroma cells
(19), have been found to home to perivascular sites, where they
may contribute to vascular development in a paracrine manner. To
investigate whether CSC also have a role in BMDC-driven
proangiogenic processes, we evaluated EPC mobilization and
tumor recruitment of various BMDC populations in mice bearing
CSC-low or CSC-high tumors.
Mice with CSC-high tumors had significantly higher levels of
circulating EPC than mice with CSC-low tumors (Fig. 4A ;
Supplementary Fig. S2), suggesting a role for CSC in mobilizing
EPC. To evaluate and visualize BMDC recruitment, lethally
irradiated nude mice were reconstituted with bone marrow from
GFP+ donors and implanted with CSC-low or CSC-high tumors.
Tumor sections were stained with a fluorescent-tagged antibody to
the vascular marker CD31, and vessel-associated BMDC (GFP+ cells
within CD31+ microvessels) were visualized by confocal microsco-
py. The fraction of microvessels with associated BMDC was not
significantly different between CSC-low and CSC-high tumors
Figure 3. Endothelial cell proliferation and tubule formation in vitro in response
to CSC-low and CSC-high conditioned medium. A and B, HUVEC proliferation
assays F IMC1121-b (anti-VEGFR2) or AMD3100. CPM, counts/min,
10 wells per group. C, HUVEC tubule formation assays F IMC1121-b or
AMD3100. Data are the sum of lengths (in pixels) of all tubules per field at 100.
Four wells per group, 10 fields per well.
Cancer Research
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(Fig. 4B). With this methodology, we are potentially visualizing
several different BMDC populations simultaneously, which may
mask significant differences in recruitment of specific BMDC
subpopulations between CSC-low and CSC-high tumors. Therefore,
we employed a second approach to evaluate recruitment of specific
BMDC subpopulations.
To evaluate recruitment of EPC, RBCC/hemangiocytes, and
TEM, flow cytometry was used on dissociated tumors from GFP-
bone marrow–reconstituted mice to identify BMDC (GFP+) in the
tumor expressing endothelial cell markers (VEGFR2+/CD31+/CD45
to identify recruited, matured EPC) or markers for RBCC/
hemangiocytes (CXCR4+/CD11b+/VEGFR1+/CD45+) or TEM
(Tie2+/CD11b+/VEGFR1+/CD45+). There was no significant differ-
ence in recruitment of RBCC/hemangiocytes or TEM between CSC-
low and CSC-high tumors (Fig. 4C), whereas significantly higher
numbers of GFP+ endothelial cells were recruited to CSC-high
tumors (Fig. 4D). This suggests that CSC promote homing and
recruitment of EPC to the tumor. The possibility remains that CSC
contribute to recruitment of other BMDC as well, although our
results suggest that in our model CSC do not significantly affect
recruitment of RBCC/hemangiocytes or TEM.
Increased expression of proangiogenic factors in CSC-high
cultures and tumors. To further our understanding of CSC-driven
angiogenic processes, we evaluated expression of two important
proangiogenic factors, VEGF and SDF1, in CSC-low and CSC-high
cultures and tumors. VEGF is a potent stimulator of local
angiogenesis and EPC mobilization (28), and SDF1 promotes EPC
recruitment and endothelial cell activity (29–31). Furthermore, we
recently found that chemotherapy induces EPC mobilization
mediated by systemic SDF1 induction (32). ELISA using condi-
tioned medium showed that more VEGF was secreted by CSC-high
cultures (Fig. 5A). SDF1 secretion was measured by Western blot of
precipitated proteins from conditioned medium. Although whole-
cell lysate of CSC-high cultures contained less SDF1 than CSC-low
culture lysate, conditioned medium precipitate from CSC-high
culture was greatly enriched for SDF1 (Fig. 5B). This suggests that,
in CSC-low tumors, SDF1 is not as highly secreted, so intracellular
levels are higher, whereas, in CSC-high tumors, SDF1 secretion is
increased, so intracellular levels are low but extracellular levels are
high. Immunofluorescent staining of established CSC-low and CSC-
high tumor sections showed that CSC-high tumors express
significantly more VEGF (Fig. 5C, top) and SDF1 (Fig. 5C, bottom).
In immunostained tumor sections, we are likely seeing an overlap
of intracellular and extracellular SDF1, which may explain why the
difference in magnitude of expression is less apparent than what
was observed by Western blot.
Figure 4. EPC mobilization and vessel incorporation in mice with CSC-low and CSC-high tumors. A, EPC in peripheral blood F DC101 (#/AL blood). Five mice
per group. B, vessel-associated BMDC (GFP+; green ) in CD31-stained microvessels (Cy3; red ; 200). Top, full field; bottom, zoomed subsection. Bar, 50 Am.
Histogram: image quantification of microvessels containing BMDC (number of GFP+, CD31+ microvessels/field divided by total number of microvessels/field; counted
manually). Five mice per group, eight fields per tumor. C and D, GFP+ RBCC/hemangiocytes, TEM (C), or endothelial cells (D ), per 10,000 tumor cells, assessed
by flow cytometry. Mice per group: (C ) 8 for CSC-low and 10 for CSC-high and (D ) 5 per group.
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CSC-derived VEGF and SDF1 are important mediators of
CSC-driven angiogenesis. To evaluate the importance of VEGF
and SDF1 in CSC-driven angiogenic processes, we performed
blocking experiments using CSC-low and CSC-high cultures and
tumors. When tumor-bearing mice were treated with the anti-
mouse VEGFR2-blocking monoclonal antibody DC101 (Fig. 6A), or
AMD3100, a small-molecule antagonist of the SDF1 receptor
CXCR4 (Fig. 6B), CSC-high tumors no longer exhibited increased
microvessel density compared with CSC-low tumors, suggesting
that VEGF and SDF1 are important in establishing the ‘‘angiogenic
advantage’’ observed in CSC-high tumors.
Because we found that CSC promote local endothelial cell
activity and EPC recruitment, we investigated the importance of
VEGF and SDF1 in each of these mechanisms of CSC-driven
angiogenesis. When HUVEC were incubated with C6 conditioned
medium and AMD3100 (Fig. 3B) or an anti-human VEGFR2-
blocking antibody (Fig. 3A), CSC-high conditioned medium no
longer stimulated higher levels of HUVEC proliferation than CSC-
low conditioned medium. Similarly, HUVEC tubule formation in
response to CSC-high conditioned medium was greatly reduced,
whereas tubule formation in response to CSC-low conditioned
medium was reduced to a much lesser degree by anti-VEGR2 and
nearly unaffected by AMD3100 (Fig. 3C). These results suggest that
stimulation of endothelial cell proliferation and tubule formation
by CSC depends in part on VEGF and SDF1. Interestingly, VEGFR2
blockade caused a decrease in tubule formation, but not
proliferation, in the CSC-low group despite that both of these
processes are influenced by VEGF. Although the reason for this
discrepancy is unclear, a likely explanation is that, within the
conditions of our assay, tubule formation in the CSC-low group was
sensitive to the amount of VEGFR2 inhibition used, whereas the
baseline level of proliferation in the CSC low group was not.
DC101 dramatically reduced the increased mobilization of EPC
previously observed in mice with CSC-high tumors (Fig. 4A).
Similarly, AMD3100 reduced EPC recruitment in CSC-high tumors
to levels similar to those in CSC-low tumors (Fig. 6C). AMD3100
had no significant effect on recruitment of RBCC/hemangiocytes or
TEM (data not shown). These results suggest that VEGF and SDF1
promote CSC-driven EPC mobilization and homing/recruitment,
respectively.
Discussion
The recent surge in interest in the CSC model has led to an
enormous amount of research seeking to identify and characterize
CSC in nearly every major disease site. This interest is largely driven
by the prediction that CSC represent a critical (and previously
unrecognized) therapeutic target. Specifically, the proliferative and
Figure 5. VEGF and SDF1 expression in CSC-low and CSC-high cultures and tumors. A, ELISA for VEGF in conditioned medium. Three replicate wells per group.
B, Western blot for SDF1 in whole-cell lysate (WCL ; loading control: h-actin) and conditioned medium. A separate gel was used for conditioned medium. C, VEGF and
SDF1 expression in C6 tumors. Top, VEGF (Cy3; red), 200; bottom, SDF1 (Cy3; red), 400. Histograms: image quantification of VEGF (top ) and SDF1 (bottom ).
Total fluorescence = total colored pixels  mean fluorescence intensity per field. Six mice per group; VEGF: five fields per tumor and SDF1: four fields per tumor.
Cancer Research
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self-renewal capabilities of CSC imply that they have important
roles in initiating and sustaining tumor growth, and evidence also
suggests a role in metastasis (1). Our work suggests that CSC may
have a role in yet another critical element of tumor progression,
that is, tumor angiogenesis. We show that tumors with a high CSC
content are more strongly angiogenic and that this results from
increased local endothelial cell activity as well as mobilization and
homing/recruitment of bone marrow–derived EPC, both of which
are dependent on increased expression of VEGF and SDF1. Our
findings are consistent with previous studies showing increased
expression of proangiogenic factors and increased stimulation of
angiogenesis by the CSC fraction compared with non-CSC tumor
cells (2–5). These findings highlight the need for continued
investigation into CSC as a potentially important target for therapy.
It may seem counterintuitive to expect that CSC, which by
definition represent a very small minority of cells in a tumor, could
make a significant contribution to tumor angiogenesis. It is
important to note, however, that, early during tumor initiation or
the seeding of a metastatic lesion, CSC would in theory represent a
much higher fraction of the overall tumor cell mass. It is in these
scenarios that the effect of CSC on angiogenesis may be significant.
Indeed, transient bursts of angiogenic activity can be sufficient to
initiate sustained tumor angiogenesis (33). Therefore, it is possible
that CSC provide the signals necessary to trip the ‘‘angiogenic
switch’’ early during the growth of primary and/or metastatic
tumors. This is an interesting possibility to consider in light of
recent evidence suggesting that glioma CSC are maintained by a
vascular niche (34). It is logical that, as part of its ability to initiate
a primary tumor or seed a metastatic lesion at distant sites with
potentially suboptimal microenvironments, a CSC has the built-in
capacity to promote the development of a niche to support its
survival. If further research uncovers a role for CSC in the
angiogenic switch, this may inform the development of new
antiangiogenic therapeutic approaches aimed at, for example,
disrupting CSC-derived angiogenic ‘‘bursts’’ during the growth of
metastatic lesions.
Another circumstance in which proangiogenic capabilities of
CSC may be important is during tumor regrowth following therapy.
Due to properties they share with normal tissue stem cells, CSC are
predicted to be resistant to many conventional cytotoxic
anticancer therapies and consequently are expected to survive
following therapy and drive tumor regrowth (35). Indeed, the CSC
fraction is enriched following radiotherapy (36) and chemotherapy
(37). The core of resistant CSC remaining after treatment
represents another scenario in which CSC would make up a
significant fraction of the overall tumor mass and consequently
may have a significant role in supporting tumor regrowth by
reinitiating angiogenesis. This concept is particularly interesting
when considered in the context of recent studies from our group.
We have found that, following treatment with cytotoxic agents
including standard chemotherapy drugs (32) and vascular-
disrupting agents (38), host-mediated systemic mobilization of
EPC from the bone marrow occurs, resulting in angiogenic rebound
and tumor cell repopulation. Considering the drug resistance and
proangiogenic properties of CSC, it is reasonable to predict that
they contribute to this observed rebound following cytotoxic
therapy. Furthermore, this angiogenic rebound and associated
tumor regrowth was blunted by combining antiangiogenic agents
with the cytotoxic treatments (32, 38). The possibility that drug-
resistant CSC contribute to the rebound process underscores the
importance of using this type of combination treatment approach
because multiple cycles of cytotoxic therapy would be predicted to
gradually enrich the proangiogenic CSC fraction in the tumor,
thereby enhancing blood vessel regrowth and tumor repopulation
in the absence of a coadministered antiangiogenic agent. Following
similar reasoning, one could predict that tumors with an inherently
larger CSC fraction would promote a more robust vascular
rebound/repopulation, making the use of antiangiogenic/cytotoxic
combination therapies particularly important with such tumors.
If these concepts are valid, they could inform treatment decisions
in the future if it becomes possible to assess the CSC fraction a
priori and possibly the development of new therapeutic strategies,
such as the addition of CSC-targeted therapies to cytotoxic/
antiangiogenic combination regimens to further blunt CSC-derived
proangiogenic signaling.
Our work may have additional implications for our understand-
ing of the contribution of bone marrow–derived EPC to tumor
Figure 6. VEGF- and SDF1-blocking experiments in mice with CSC-low and
CSC-high tumors. A and B, image quantification of microvessel density in
tumors F DC101 (anti-VEGFR2) or AMD3100: number of CD31+ structures per
field (counted manually). Five mice per group, eight fields per tumor. C,
quantification of vessel-associated, bone marrow–derived (GFP+) endothelial
cells (CD31+/VEGFR2+/CD45) F AMD3100 per 10,000 tumor cells by flow
cytometry. Five mice per group, except CSC-low control (n = 3).
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vascular development. Many studies have suggested that EPC
residing in the bone marrow can be recruited to the tumor in
response to tumor-derived cytokines, where they contribute to
vascular development by incorporating into the walls of nascent
capillaries (6). The significance of this contribution is still a matter
of considerable debate, however. Although some studies have
shown a significant role for EPC in tumor angiogenesis in certain
models (7–13), and previous work from our group has shown that a
robust recruitment of these cells occurs following cytotoxic therapy
(32, 38), in many cases, the level of EPC incorporation into tumor
vessels is reported to be very low or even nonexistent (39–45),
calling into question the general relevance of these cells to tumor
blood vessel growth. Our work suggests that tumors with a larger
CSC fraction recruit greater numbers of EPC, which raises the
possibility that EPC recruitment may play a more significant role in
tumor vascular development in tumors with a large CSC fraction.
The correlation between CSC fraction and EPC recruitment could
possibly explain some of the discrepancies in the observed levels of
EPC recruitment between various studies, because the size of the
CSC fraction is also reported to vary significantly between different
tumor types as well as between individuals with the same tumor
type (1). Further study of the relationship between CSC and EPC is
warranted, as both of these cell types, although currently
incompletely understood, have potentially major implications for
tumor biology and therapy.
Significant work is required before we can fully understand the
role of the CSC fraction in tumor angiogenesis. It will be important
to study the mechanisms, timing, and extent of involvement of CSC
in the various angiogenic processes, as these will all have
implications for our understanding of tumor vascular development
and CSC biology as well as our approach to various anticancer
therapies including antiangiogenic and CSC-targeted therapies. As
with many aspects of CSC biology, however, advancement in this
area will depend primarily on the continued development of better
models and improved techniques to better identify, isolate, and
track CSC throughout tumor development.
Disclosure of Potential Conflicts of Interest
R.M. Hoffman: Chief Executive Officer of AntiCancer, Inc. The other authors
disclosed no potential conflicts of interest.
Acknowledgments
Received 1/15/09; revised 6/22/09; accepted 7/18/09; published OnlineFirst 9/8/09.
Grant support: Canadian Institutes for Health Research, Canadian Cancer Society
Research Institute, Ontario Institute for Cancer Research, and a sponsored research
agreement with ImClone Systems (R.S. Kerbel); Canadian Institutes for Health
Research doctoral research award and Ontario Graduate Scholarship (C. Folkins).
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Cassandra Cheng for excellent secretarial assistance.
Cancer Research
Cancer Res 2009; 69: (18). September 15, 2009 7250 www.aacrjournals.org
References
1. Visvader JE, Lindeman GJ. Cancer stem cells in solid
tumours: accumulating evidence and unresolved ques-
tions. Nat Rev Cancer 2008;8:755–68.
2. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like
glioma cells promote tumor angiogenesis through
vascular endothelial growth factor. Cancer Res 2006;66:
7843–8.
3. Yao XH, Ping YF, Chen JH, et al. Glioblastoma stem
cells produce vascular endothelial growth factor by
activation of a G-protein coupled formylpeptide recep-
tor FPR. J Pathol 2008;215:369–76.
4. Ponti D, Costa A, Zaffaroni N, et al. Isolation and
in vitro propagation of tumorigenic breast cancer cells
with stem/progenitor cell properties. Cancer Res 2005;
65:5506–11.
5. Pellegatta S, Poliani PL, Corno D, et al. Neuro-
spheres enriched in cancer stem-like cells are highly
effective in eliciting a dendritic cell-mediated immune
response against malignant gliomas. Cancer Res 2006;
66:10247–52.
6. Hillen F, Griffioen AW. Tumour vascularization:
sprouting angiogenesis and beyond. Cancer Metastasis
Rev 2007;26:489–502.
7. Duda DG, Cohen KS, Kozin SV, et al. Evidence for
incorporation of bone marrow-derived endothelial cells
into perfused blood vessels in tumors. Blood 2006;107:
2774–6.
8. Lyden D, Hattori K, Dias S, et al. Impaired recruitment
of bone-marrow-derived endothelial and hematopoietic
precursor cells blocks tumor angiogenesis and growth.
Nat Med 2001;7:1194–201.
9. Ciarrocchi A, Jankovic V, Shaked Y, et al. Id1 restrains
p21 expression to control endothelial progenitor cell
formation. PLoS ONE 2007;2:e1338.
10. Nolan DJ, Ciarrocchi A, Mellick AS, et al. Bone
marrow-derived endothelial progenitor cells are a major
determinant of nascent tumor neovascularization.
Genes Dev 2007;21:1546–58.
11. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss
R. Chemokines direct endothelial progenitors into
tumor neovessels. Proc Natl Acad Sci U S A 2005;102:
18111–6.
12. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell
K, Mittal V. Endothelial progenitor cells control the
angiogenic switch in mouse lung metastasis. Science
2008;319:195–8.
13. Garcia-Barros M, Paris F, Cordon-Cardo C, et al.
Tumor response to radiotherapy regulated by endothe-
lial cell apoptosis. Science 2003;300:1155–9.
14. Jin DK, Shido K, Kopp HG, et al. Cytokine-mediated
deployment of SDF-1 induces revascularization through
recruitment of CXCR4+ hemangiocytes. Nat Med 2006;
12:557–67.
15. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced
adult neovascularization: recruitment, retention, and
role of accessory cells. Cell 2006;124:175–89.
16. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies
a hematopoietic lineage of proangiogenic monocytes
required for tumor vessel formation and a mesenchymal
population of pericyte progenitors. Cancer Cell 2005;8:
211–26.
17. Venneri MA, De PM, Ponzoni M, et al. Identification
of proangiogenic TIE2-expressing monocytes (TEMs) in
human peripheral blood and cancer. Blood 2007;109:
5276–85.
18. Conejo-Garcia JR, Benencia F, Courreges MC, et al.
Tumor-infiltrating dendritic cell precursors recruited by
a h-defensin contribute to vasculogenesis under the
influence of Vegf-A. Nat Med 2004;10:950–8.
19. Udagawa T, Puder M, Wood M, Schaefer BC,
D’Amato RJ. Analysis of tumor-associated stromal cells
using SCID GFP transgenic mice: contribution of local
and bone marrow-derived host cells. FASEB J 2006;20:
95–102.
20. Kondo T, Setoguchi T, Taga T. Persistence of a small
subpopulation of cancer stem-like cells in the C6
glioma cell line. Proc Natl Acad Sci U S A 2004;101:
781–6.
21. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel
RS. Anticancer therapies combining antiangiogenic and
tumor cell cytotoxic effects reduce the tumor stem-like
cell fraction in glioma xenograft tumors. Cancer Res
2007;67:3560–4.
22. Donzella GA, Schols D, Lin SW, et al. AMD3100, a
small molecule inhibitor of HIV-1 entry via the CXCR4
co-receptor. Nat Med 1998;4:72–7.
23. Lu D, Shen J, Vil MD, et al. Tailoring in vitro selection
for a picomolar affinity human antibody directed
against vascular endothelial growth factor receptor 2
for enhanced neutralizing activity. J Biol Chem 2003;278:
43496–507.
24. Ebos JM, Tran J, Master Z, et al. Imatinib mesylate
(STI-571) reduces Bcr-Abl-mediated vascular endotheli-
al growth factor secretion in chronic myelogenous
leukemia. Mol Cancer Res 2002;1:89–95.
25. Yang M, Reynoso J, Jiang P, Li L, Moossa AR, Hoffman
RM. Transgenic nude mouse with ubiquitous green
fluorescent protein expression as a host for human
tumors. Cancer Res 2004;64:8651–6.
26. Bertolini F, Paul S, Mancuso P, et al. Maximum
tolerable dose and low-dose metronomic chemotherapy
have opposite effects on the mobilization and viability
of circulating endothelial progenitor cells. Cancer Res
2003;63:4342–6.
27. Prewett M, Huber J, Li Y, et al. Antivascular
endothelial growth factor receptor ( fetal liver kinase
1) monoclonal antibody inhibits tumor angiogenesis
and growth of several mouse and human tumors.
Cancer Res 1999;59:5209–18.
28. Hicklin DJ, Ellis LM. Role of the vascular endothelial
growth factor pathway in tumor growth and angiogen-
esis. J Clin Oncol 2005;23:1011–27.
29. Mirshahi F, Pourtau J, Li H, et al. SDF-1 activity on
microvascular endothelial cells: consequences on an-
giogenesis in in vitro and in vivo models. Thromb Res
2000;99:587–94.
30. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA.
Tumor stromal-derived factor-1 recruits vascular pro-
genitors to mitotic neovasculature, where microenvi-
ronment influences their differentiated phenotypes.
Cancer Res 2006;66:9054–64.
31. Reddy K, Zhou Z, Jia SF, et al. Stromal cell-derived
factor-1 stimulates vasculogenesis and enhances
Ewing’s sarcoma tumor growth in the absence of
vascular endothelial growth factor. Int J Cancer 2008;
123:831–7.
32. Shaked Y, Henke E, Roodhart JM, et al. Rapid
chemotherapy-induced acute endothelial progenitor cell
mobilization: implications for antiangiogenic drugs as
chemosensitizing agents. Cancer Cell 2008;14:263–73.
CSC Promote Tumor Vascular Development
www.aacrjournals.org 7251 Cancer Res 2009; 69: (18). September 15, 2009
33. Indraccolo S, Stievano L, Minuzzo S, et al. Interrup-
tion of tumor dormancy by a transient angiogenic burst
within the tumor microenvironment. Proc Natl Acad Sci
U S A 2006;103:4216–21.
34. Calabrese C, Poppleton H, Kocak M, et al. A
perivascular niche for brain tumor stem cells. Cancer
Cell 2007;11:69–82.
35. Dean M, Fojo T, Bates S. Tumour stem cells and drug
resistance. Nat Rev Cancer 2005;5:275–84.
36. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells
promote radioresistance by preferential activation of the
DNA damage response. Nature 2006;444:756–60.
37. Dylla SJ, Beviglia L, Park IK, et al. Colorectal cancer
stem cells are enriched in xenogeneic tumors following
chemotherapy. PLoS ONE 2008;3:e2428.
38. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-
induced acute recruitment of circulating endothelial
progenitor cells to tumors. Science 2006;313:1785–7.
39. Machein MR, Renninger S, de Lima-Hahn E, Plate
KH. Minor contribution of bone marrow-derived
endothelial progenitors to the vascularization of murine
gliomas. Brain Pathol 2003;13:582–97.
40. Ruzinova MB, Schoer RA, Gerald W, et al. Effect of
angiogenesis inhibition by Id loss and the contribution
of bone-marrow-derived endothelial cells in spontane-
ous murine tumors. Cancer Cell 2003;4:277–89.
41. Gothert JR, Gustin SE, van Eekelen JA, et al.
Genetically tagging endothelial cells in vivo : bone
marrow-derived cells do not contribute to tumor
endothelium. Blood 2004;104:1769–77.
42. Rajantie I, IlmonenM, Alminaite A, OzerdemU, Alitalo
K, Salven P. Adult bone marrow-derived cells recruited
during angiogenesis comprise precursors for periendo-
thelial vascular mural cells. Blood 2004;104:2084–6.
43. Peters BA, Diaz LA, Polyak K, et al. Contribution of
bone marrow-derived endothelial cells to human tumor
vasculature. Nat Med 2005;11:261–2.
44. Larrivee B, Niessen K, Pollet I, et al. Minimal
contribution of marrow-derived endothelial precursors
to tumor vasculature. J Immunol 2005;175:2890–9.
45. Purhonen S, Palm J, Rossi D, et al. Bone marrow-
derived circulating endothelial precursors do not
contribute to vascular endothelium and are not needed
for tumor growth. Proc Natl Acad Sci U S A 2008;105:
6620–5.
